FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890743632> ?p ?o ?g. }

• W2890743632 endingPage "518" @default.
• W2890743632 startingPage "511" @default.
• W2890743632 abstract "Objective To investigate the use of 5α‐reductase inhibitors (5 ARI s) and α‐blockers among men with benign prostatic hyperplasia ( BPH ) in relation to prostate cancer ( PC a) incidence, severity and mortality. Patients and Methods A retrospective 20‐year cohort study in men residing in Saskatchewan, aged 40–89 years, with a BPH ‐coded medical claim between 1995 and 2014, was conducted. Cox proportional hazards regression was used to compare incidence of PC a diagnosis, metastatic PC a, Gleason score 8–10 PC a, and PC a mortality among 5 ARI users ( n = 4 571), α‐blocker users ( n = 7 764) and non‐users ( n = 11 677). Results In comparison with both non‐users and α‐blocker users, 5 ARI users had a ~40% lower risk of a PC a diagnosis (11.0% and 11.4% vs 5.8%, respectively), and α‐blocker users had an 11% lower risk of a PC a diagnosis compared with non‐users. Overall, the incidence of metastatic PC a and PC a mortality was not significantly different among 5 ARI or α‐blocker users compared with non‐users (adjusted hazard ratios [HR] of metastatic PCa: 1.12 and 1.13, respectively, and PCa mortality: 1.11 and 1.18, respectively, P > 0.05 for both drugs), but both 5ARI and a‐blocker users had ~30% higher risk of Gleason score 8–10 cancer, adjusted HR 1.37, 95% confidence interval [ CI ] 1.03–1.82, P = 0.03, and adjusted HR 1.28, 95% CI 1.03–1.59, P = 0.02, respectively compared with non‐users. Conclusion The use of 5 ARI s was associated with lower risk of PC a diagnosis, regardless of comparison group. Risk of high grade PC a was higher among both 5 ARI users and α‐blocker users compared with non‐users; however, this did not translate into higher risk of PC a mortality." @default.
• W2890743632 created "2018-09-27" @default.
• W2890743632 creator A5030530617 @default.
• W2890743632 creator A5034811772 @default.
• W2890743632 creator A5046547526 @default.
• W2890743632 creator A5056766924 @default.
• W2890743632 creator A5078493330 @default.
• W2890743632 creator A5087211808 @default.
• W2890743632 creator A5089954551 @default.
• W2890743632 date "2018-10-24" @default.
• W2890743632 modified "2023-10-16" @default.
• W2890743632 title "Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality" @default.
• W2890743632 cites W1562814518 @default.
• W2890743632 cites W1988729953 @default.
• W2890743632 cites W2002664683 @default.
• W2890743632 cites W2012608816 @default.
• W2890743632 cites W2016677782 @default.
• W2890743632 cites W2020095621 @default.
• W2890743632 cites W2034621471 @default.
• W2890743632 cites W2042589569 @default.
• W2890743632 cites W2059927586 @default.
• W2890743632 cites W2065348491 @default.
• W2890743632 cites W2081597080 @default.
• W2890743632 cites W2082304772 @default.
• W2890743632 cites W2089030366 @default.
• W2890743632 cites W2093593899 @default.
• W2890743632 cites W2127031670 @default.
• W2890743632 cites W2129302529 @default.
• W2890743632 cites W2144956729 @default.
• W2890743632 cites W2155530804 @default.
• W2890743632 cites W2170621307 @default.
• W2890743632 cites W2341036690 @default.
• W2890743632 cites W2476646956 @default.
• W2890743632 cites W2521833203 @default.
• W2890743632 cites W2540045475 @default.
• W2890743632 cites W3135529189 @default.
• W2890743632 cites W4362207783 @default.
• W2890743632 doi "https://doi.org/10.1111/bju.14534" @default.
• W2890743632 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6397052" @default.
• W2890743632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30216624" @default.
• W2890743632 hasPublicationYear "2018" @default.
• W2890743632 type Work @default.
• W2890743632 sameAs 2890743632 @default.
• W2890743632 citedByCount "16" @default.
• W2890743632 countsByYear W28907436322018 @default.
• W2890743632 countsByYear W28907436322019 @default.
• W2890743632 countsByYear W28907436322020 @default.
• W2890743632 countsByYear W28907436322021 @default.
• W2890743632 countsByYear W28907436322022 @default.
• W2890743632 countsByYear W28907436322023 @default.
• W2890743632 crossrefType "journal-article" @default.
• W2890743632 hasAuthorship W2890743632A5030530617 @default.
• W2890743632 hasAuthorship W2890743632A5034811772 @default.
• W2890743632 hasAuthorship W2890743632A5046547526 @default.
• W2890743632 hasAuthorship W2890743632A5056766924 @default.
• W2890743632 hasAuthorship W2890743632A5078493330 @default.
• W2890743632 hasAuthorship W2890743632A5087211808 @default.
• W2890743632 hasAuthorship W2890743632A5089954551 @default.
• W2890743632 hasBestOaLocation W28907436322 @default.
• W2890743632 hasConcept C120665830 @default.
• W2890743632 hasConcept C121332964 @default.
• W2890743632 hasConcept C121608353 @default.
• W2890743632 hasConcept C126322002 @default.
• W2890743632 hasConcept C126894567 @default.
• W2890743632 hasConcept C167135981 @default.
• W2890743632 hasConcept C207103383 @default.
• W2890743632 hasConcept C2777562237 @default.
• W2890743632 hasConcept C2780192828 @default.
• W2890743632 hasConcept C29456083 @default.
• W2890743632 hasConcept C44249647 @default.
• W2890743632 hasConcept C50382708 @default.
• W2890743632 hasConcept C61511704 @default.
• W2890743632 hasConcept C71924100 @default.
• W2890743632 hasConcept C72563966 @default.
• W2890743632 hasConceptScore W2890743632C120665830 @default.
• W2890743632 hasConceptScore W2890743632C121332964 @default.
• W2890743632 hasConceptScore W2890743632C121608353 @default.
• W2890743632 hasConceptScore W2890743632C126322002 @default.
• W2890743632 hasConceptScore W2890743632C126894567 @default.
• W2890743632 hasConceptScore W2890743632C167135981 @default.
• W2890743632 hasConceptScore W2890743632C207103383 @default.
• W2890743632 hasConceptScore W2890743632C2777562237 @default.
• W2890743632 hasConceptScore W2890743632C2780192828 @default.
• W2890743632 hasConceptScore W2890743632C29456083 @default.
• W2890743632 hasConceptScore W2890743632C44249647 @default.
• W2890743632 hasConceptScore W2890743632C50382708 @default.
• W2890743632 hasConceptScore W2890743632C61511704 @default.
• W2890743632 hasConceptScore W2890743632C71924100 @default.
• W2890743632 hasConceptScore W2890743632C72563966 @default.
• W2890743632 hasFunder F4320332161 @default.
• W2890743632 hasIssue "3" @default.
• W2890743632 hasLocation W28907436321 @default.
• W2890743632 hasLocation W28907436322 @default.
• W2890743632 hasLocation W28907436323 @default.
• W2890743632 hasLocation W28907436324 @default.
• W2890743632 hasOpenAccess W2890743632 @default.
• W2890743632 hasPrimaryLocation W28907436321 @default.
• W2890743632 hasRelatedWork W1727188710 @default.

• next